When I use a word . . . The languages of medicines—trade names, proprietary names, or brand-names

Jeffrey K Aronson

DOI: https://doi.org/10.1136/bmj.q1206

2024-06-01

BMJ

Abstract:Naming medicinesAs I have previously outlined,1 a medicine can have up to four types of names, distinguishing what a medicine or its name is from what the medicine or its name is called:● name 1—what the medicine is, as indicated by its full chemical name;● name 2—what the medicine's name is, i.e. its generic name, as assigned in a specific country, such as a British Approved Name, or by the World Health Organization, its International Nonproprietary Name (INN);● name 3—what the medicine's name is called, i.e. any brand-names assigned by a pharmaceutical company;● name 4—what the medicine itself is called, i.e. colloquial names given to it by the general public, such as street names for recreational drugs and drugs of abuse.Individual medicines have both chemical names and generic names, such as British Approved Names (BANs) and International Nonproprietary names (INNs). Medicinal products are often referred to by the generic names...

medicine, general & internal

What problem does this paper attempt to address?

The paper primarily discusses the issue of drug naming, particularly the brand names of drugs (also known as trade names or proprietary names). The author first outlines the four levels of drug naming: chemical name, generic name, brand name, and public colloquial name, and focuses on the related issues of brand names.

The paper mentions that the brand name of a drug is a specific name given to the product by the pharmaceutical company, and these names usually have trademark status. The selection of brand names is constrained by guidelines issued by regulatory agencies such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the Food and Drug Administration (FDA) in the US. These guidelines aim to ensure that brand names do not mislead consumers and comply with certain legal requirements.

Specifically, the paper explores the following aspects:
1. **History and Definition of Brand Names**: Introduces the historical evolution and definitions of the terms "trade name," "proprietary name," and "brand name."
2. **Regulatory Guidelines**: Details the specific guidelines from the MHRA for selecting drug brand names, including what brand names should not contain (such as implications of beneficial effects, specific ingredients, etc.), and some recommended words to avoid (such as words indicating strength, rapid action, etc.).
3. **Special Considerations for Over-the-Counter Drugs**: For over-the-counter drugs, brand names can include some information about indications but must not contain misleading implications.
4. **Liability**: Even if a brand name is accepted by regulatory agencies, manufacturers still need to bear the responsibility for any harm caused by the product.

In summary, this paper aims to help readers understand the principles and considerations behind drug naming, as well as the requirements of relevant regulations, through an in-depth analysis of drug brand names.